Ocular Therapeutix (NASDAQ:OCUL) Receives "Outperform" Rating from Royal Bank Of Canada

Key Points

• Royal Bank of Canada reiterated an Outperform rating on Ocular Therapeutix with a $30 price target implying about 206% upside, while the analyst consensus remains a Moderate Buy with an average target of $23.78.
• Company catalysts include positive Phase‑3 SOL‑1 Week‑52 data and an advancing NDA plan for AXPAXLI, with SOL‑R topline readout expected in Q1 2027 and $666.7M cash runway into 2028 to support commercialization efforts.
• Near‑term headwinds: Q1 results missed estimates (EPS ($0.40) vs ($0.32) and revenue $10.79M vs $12.72M), and insiders sold roughly 185,731 shares (~$1.65M) in the past 90 days while the stock trades near $9.80 (market cap ~$2.14B).

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report)'s stock had its "outperform" rating reiterated by investment analysts at Royal Bank Of Canada in a report issued on Wednesday,Benzinga reports. They currently have a $30.00 price target on the biopharmaceutical company's stock. Royal Bank Of Canada's target price indicates a potential upside of 206.28% from the stock's current price.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Ocular Therapeutix in a report on Tuesday, April 21st. Wall Street Zen lowered shares of Ocular Therapeutix from a "hold" rating to a "sell" rating in a report on Saturday, February 28th. Citigroup restated an "outperform" rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Needham & Company LLC lowered their target price on shares of Ocular Therapeutix from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Friday, February 20th. Finally, Chardan Capital restated a "buy" rating and issued a $21.00 target price on shares of Ocular Therapeutix in a report on Wednesday, February 18th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $23.78.

Ocular Therapeutix Trading Up 0.9%

OCUL traded up $0.09 during trading on Wednesday, reaching $9.80. 1,109,286 shares of the stock traded hands, compared to its average volume of 5,381,789. The company has a quick ratio of 15.32, a current ratio of 15.39 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $2.14 billion, a PE ratio of -6.75 and a beta of 0.93. The stock's 50-day moving average is $9.04 and its 200 day moving average is $10.54. Ocular Therapeutix has a 12 month low of $6.23 and a 12 month high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The company had revenue of $10.79 million for the quarter, compared to analyst estimates of $12.72 million. During the same quarter in the prior year, the company posted ($0.38) EPS. Ocular Therapeutix's revenue for the quarter was up .8% on a year-over-year basis. Equities analysts anticipate that Ocular Therapeutix will post -1.29 earnings per share for the current year.

Insider Transactions at Ocular Therapeutix

In other Ocular Therapeutix news, insider Sanjay Nayak sold 10,348 shares of the stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $9.04, for a total value of $93,545.92. Following the completion of the sale, the insider owned 332,412 shares in the company, valued at approximately $3,005,004.48. This trade represents a 3.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Pravin Dugel sold 20,056 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $8.28, for a total transaction of $166,063.68. Following the completion of the sale, the insider owned 3,013,022 shares of the company's stock, valued at approximately $24,947,822.16. This trade represents a 0.66% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 185,731 shares of company stock worth $1,653,407. Company insiders own 2.30% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of OCUL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Ocular Therapeutix by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company's stock valued at $686,000 after acquiring an additional 5,156 shares during the period. Caxton Associates LLP bought a new position in shares of Ocular Therapeutix during the 1st quarter valued at approximately $248,000. Creative Planning grew its position in shares of Ocular Therapeutix by 21.5% during the 2nd quarter. Creative Planning now owns 21,410 shares of the biopharmaceutical company's stock valued at $199,000 after acquiring an additional 3,791 shares during the period. JPMorgan Chase & Co. grew its position in shares of Ocular Therapeutix by 110.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 712,100 shares of the biopharmaceutical company's stock valued at $6,608,000 after acquiring an additional 374,269 shares during the period. Finally, Prudential Financial Inc. grew its position in shares of Ocular Therapeutix by 57.9% during the 2nd quarter. Prudential Financial Inc. now owns 18,700 shares of the biopharmaceutical company's stock valued at $174,000 after acquiring an additional 6,855 shares during the period. 59.21% of the stock is owned by institutional investors.

Key Ocular Therapeutix News

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Phase 3 SOL‑1: company announced positive SOL‑1 Week‑52 Phase 3 results and is advancing plans to submit an NDA for AXPAXLI based on those data — a major potential revenue/valuation driver if approved. Ocular Therapeutix Reports First Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: SOL‑R / SOL‑X timelines: SOL‑R Phase 3 (non‑inferiority) remains on track for topline readout in Q1 2027; enrollment has begun in the SOL‑X long‑term extension for subjects completing two‑year follow‑up — these milestones provide clear upcoming binary data events. Ocular Therapeutix outlines SOL‑R top line data in Q1 2027 while advancing AXPAXLI NDA plan
• Positive Sentiment: Balance sheet and commercialization prep: cash of $666.7M (runway into 2028) and accelerated commercial preparedness efforts mean lower near‑term financing risk and readiness to commercialize if approval is secured; Investor Day scheduled for June 17 may provide further regulatory/commercial clarity. Ocular Therapeutix Reports First Quarter 2026 Financial Results and Business Highlights
• Neutral Sentiment: Earnings call context: management discussed Q1 results and program timelines on the earnings call (useful for details on commercialization timing, FDA interactions and spend cadence). Investors should review the call transcript for guidance comments that could affect near‑term sentiment. Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 financials missed estimates: reported loss ~($0.40)/share and revenue of $10.79M vs. consensus ~ $12.7M — the EPS and revenue miss is a short‑term headwind and explains selling pressure despite pipeline positives. Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.